Saturday 17 October 2026
Export RDHL’s income statement to Excel — free account
Redhill Biopharma Ltd.
RDHL Healthcare Drug Manufacturers Specialty & Generic
0.48
0.02
−4.00%
Follow RDHL
| Older periods | Jun '23 | Jun '24 | Jun '25 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
4 | — | — | — |
| (181.89%) | 0.00% | 0.00% | 0.00% | ||
| 7.59% | 0.00% | 0.00% | 0.00% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(858.65%) | 0.00% | 0.00% | 0.00% | |
Average Days of Receivables |
34.67 | 0.00 | 0.00 | — | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | — | |
Free Cash Flow |
(33.53) | (31.24) | (19.66) | — | |
Capital Expenditures |
(0.19) | (0.03) | (0.01) | — | |
| Other line items | |||||
Cash ROIC |
(170.88%) | (386.84%) | 1,418.54% | 0.00% | |
Accounts Receivable Turnover |
1.67 | 0.00 | 0.00 | — | |
Accounts Payable Turnover |
5.29 | 0.00 | 0.00 | 0.00 | |
Inventory Turnover |
2.38 | 0.00 | 0.00 | — | |
Average Days of Payables |
57.33 | 0.00 | 0.00 | 0.00 | |
Days of Inventory on Hand |
90.98 | 0.00 | 0.00 | — | |
Tax Rate |
0.00 | — | — | — | |
Research and Development Expense of Revenue |
16.53% | — | — | — | |
Selling, General and Administrative Expense of Revenue |
144.88% | — | — | — | |
Share Based Compensation of Revenue |
12.25% | 0.00% | 0.00% | — | |
Interest Coverage |
0.00 | — | — | — | |
Operating CF/Net income |
(4.33) | 0.00 | 0.00 | — | |
Depreciation/Fixed assets |
268.87 | 54.66 | 37.19 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | — | |
Revenue per Share |
0.00 | — | — | — | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | — | |
Capex per Share |
0.00 | 0.00 | 0.00 | — | |
Capex to Sales |
0.01 | 0.00 | 0.00 | — |
Columns are period end dates · fundamentals updated 2 Oct 2026